Glenmark receives tentative approval for generic version of Savella Tablets

31 Mar 2017 Evaluate

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (USFDA) for Milnacipran Hydrochloride Tablets, 12.5 mg, 25 mg, 50 mg and 100 mg, the generic version of Savella Tablets, 12.5 mg, 25 mg, 50 mg and 100 mg of Allergan Sales, LLC.

According to IMS Health sales data for the 12 month period ending February 2017, the Savella Tablets, 12.5 mg, 25 mg, 50 mg and 100 mg market achieved annual sales of approximately $154.4 million.

Glenmark’s current portfolio consists of 113 products authorized for distribution in the US marketplace and 65 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.


Glenmark Pharma Share Price

1021.15 15.00 (1.49%)
17-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1530.00
Dr. Reddys Lab 5802.00
Cipla 1399.35
Zydus Lifesciences 1051.90
Lupin 1653.75
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.